News
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Vita 34 publishes preliminary figures on the course of business in 2023
Vita 34 AG publishes preliminary figures on the course of business in 2023, reporting Group revenue of EUR 76.8 million and preliminary EBITDA of EUR 4.0 million, which fell short of expectations due to extraordinary charges. The company plans to invest in cell and gene therapies and CDMO following the merger with PBKM -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Vita 34 AG (von Montega AG): Kaufen (zuvor: Halten)
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Vita 34 AG (von Montega AG): Halten
-
-
COMMUNIQUÉ DE PRESSE
Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate
-
COMMUNIQUÉ DE PRESSE
Original-Research: Vita 34 AG (von Montega AG): Halten
